Journal articleClin Cancer Res2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
- Journal
- Clin Cancer Res
- Published
- 1 December 2022
- Citations
- 114
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 6
- 11 Solid Tumor Therapeutics Program P30CA091842↗
- The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670↗
- COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY R01CA203890↗
- Exploiting Integrin Signaling to Overcome Resistance to Immunotherapy R01CA244938↗
- Targeting Focal Adhesion Kinase to Improve RT-inducted Tumor Immunity R01CA248917↗
- Re-wiring PDAC Tumor Immunity Through Dendritic Cells R01CA262506↗